Login
REGENXBIO NASDAQ: RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
| Name | REGENXBIO |
| Ticker | RGNX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 29.95 |
| 52W Low/High | 21.50 / 54.20 |
| Market cap | 1.1 B |
| 1Y Total Return |
-24.94%
Below Average |
| 1Y Volatility |
75.37%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
Details
| Ticker | RGNX |
| Name | REGENXBIO |
| ISIN | US75901B1070 |
| CUSIP | 75901B107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/18/20
| Close Price | 29.95 |
| 52W Low/High | 21.50 / 54.20 |
| Market cap | 1.1 B |
| 1Y Total Return |
-24.94%
Below Average |
| 1Y Volatility |
75.37%
More Risk |
| Beta | 1.64 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -222.2% |
| Cash from Op. / Cur. Liabilities | -2.78 |
| Diluted Earnings / Share | -3.65 |
| ROE | - |
| ROIC | -33.9% |
| Price / Revenue | 18.4 |
| Price / Book | 2.8 |
| Price / CF | -10.0 |
| Current Ratio | 8.2 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | 0.03 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
61
|
55
|
176
|
9
|
8
|
-
|
|
| Gross Profit |
46
|
50
|
169
|
7
|
7
|
-
|
|
| R&D |
145
|
98
|
68
|
59
|
27
|
-
|
|
| EBITDA |
-130
|
-43
|
85
|
-73
|
-38
|
-
|
|
| Operating Income |
-156
|
-93
|
70
|
-77
|
-39
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
78
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
37
|
37
|
35
|
31
|
26
|
-
|
|
| EPS exc. Extra |
-3.65
|
-1.43
|
2.16
|
-2.72
|
0.41
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
450
|
529
|
336
|
224
|
206
|
89
|
|
| Cash, Eq & Invt ShortTerm |
271
|
343
|
287
|
162
|
94
|
85
|
|
| Total Current Assets |
329
|
359
|
293
|
166
|
98
|
87
|
|
| Total Non-Current Assets |
121
|
170
|
43
|
59
|
108
|
2
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
52
|
35
|
19
|
13
|
10
|
6
|
|
| Total Current Liabilities |
40
|
25
|
17
|
11
|
9
|
6
|
|
| Long Term Debt |
12
|
10
|
2
|
1
|
1
|
0
|
|
| Shareholder equity |
398
|
495
|
317
|
212
|
196
|
-29
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-112
|
-77
|
97
|
-59
|
-29
|
-
|
|
| Depreciation |
8
|
6
|
3
|
2
|
0
|
-
|
|
| Cash from Investing |
144
|
-177
|
-58
|
5
|
-171
|
-
|
|
| Capex |
12
|
16
|
8
|
11
|
2
|
-
|
|
| Cash from Financing |
7
|
203
|
10
|
82
|
145
|
-
|
|
| Stock Issued |
7
|
203
|
10
|
83
|
145
|
-
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
-20
|
-342
|
153
|
-121
|
-101
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
44.4%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
138.2%
|
-
|
-
|
-
|
|
| Current Ratio |
8.2
|
14.6
|
17.4
|
14.5
|
10.7
|
14.4
|
|
| Financial Leverage D/E |
0.03
|
0.01
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-33.9%
|
-14.7%
|
47.0%
|
-45.9%
|
-45.9%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
29.5%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available